Shares of Alembic Pharmaceuticals rallied as much as 20% on Wednesday, November 4, after the drugmaker reported a strong set of results for the September quarter (Q2 FY27), with robust growth in both revenue and profitability. Revenue rose 36.3% year-on-year to ₹2,603 crore from ₹1,910 crore in the corresponding quarter last year. Profit after tax surged 81.1% to ₹335 crore from ₹185 crore, while EBITDA climbed 78.7% to ₹563 crore from ₹315 crore. The EBITDA margin expanded to 21.6% from 16.5% a year earlier, an improvement of 510 basis points. The US business was the standout. US formulations revenue increased 77% to ₹1,003 crore, supported by three product launches in the US market during the quarter. The India branded business reported revenue of ₹725 crore, up 14% year-on-year, while the ex-US international business grew 12% to ₹440 crore. The active pharmaceutical ingredients (API) business posted 39% growth to ₹436 crore. Alembic also received one abbreviated new drug application (ANDA) approval during the quarter, taking its cumulative approvals to 245. Managing Director Pranav Amin said the company delivered another quarter of strong, broad-based growth and improved profitability, with the US business driven by strong volume growth and new launches and the India business regaining momentum. He added that after a strong first half, Alembic is well positioned to sustain growth and create long-term value for stakeholders. The stock hit its 20% upper circuit at ₹965 on the BSE versus a previous close of ₹804, before paring some gains to trade about 13% higher in the afternoon session.
Home / News
Alembic Pharma Shares Jump 20% as Q2 Profit Rises 81% on US Surge
• Alembic Pharmaceuticals shares rallied as much as 20% on Wednesday after Q2 FY27 profit after tax rose 81.1% to ₹335 crore. • Revenue grew 36.3% year-on-year to ₹2,603 crore, while EBITDA rose 78.7% to ₹563 crore and margin expanded to 21.6% from 16.5%. • US formulations revenue jumped 77% to ₹1,003 crore, helped by three US product launches during the quarter. • India branded business grew 14% to ₹725 crore; API revenue rose 39% to ₹436 crore.